Following cancer combo deal with Bristol-Myers, Taris gets $25M Series B
Just one day after announcing a cancer combo collaboration with Bristol-Myers Squibb, Taris Biomedical has raised $25 million in a new Series B round backed in part by the pharma giant.
Some of that new cash will be used to take the company’s lead program, called TAR-200, through early clinical trials. TAR-200 has been designed to release gemcitabine, a chemotherapeutic agent, in the bladder continuously over seven days.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.